Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors
A Phase 1 Dose Escalation Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors
Sponsor: PRAECIS Pharmaceuticals Inc.
Terminated
terminated due to corporate transaction.
This PHASE1 trial investigates Non-Hodgkin's Lymphoma, and Solid Tumors and is currently terminated or withdrawn. PRAECIS Pharmaceuticals Inc. leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Terminated PHASE1
-
Jun 2018 — Sep 2020 [monthly]
Terminated PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1
First recorded
Dec 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- PRAECIS Pharmaceuticals Inc.
For direct contact, visit the study record on ClinicalTrials.gov .